Immune Checkpoint Inhibitors: Altering the Landscape of Treatment in Hepatobiliary Cancers

Join us for this dynamic live-streamed symposium, featuring an expert faculty panel, to get up to date on the latest clinical data informing optimal use of immune checkpoint inhibitors in treating patients with HCC and biliary tract cancers. Sign up now!

Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

  • Current Use and Ongoing Trials of Immune Checkpoint Inhibitors for:
    • Advanced HCC: First-Line Therapy
    • Advanced HCC: Second-Line Therapy and Beyond
    • Early- or Intermediate-Stage HCC
    • Biliary Tract Cancers
  • Concluding Remarks and Audience Question and Answer Session

Events

Date / Time
Event Details

Faculty

Faculty
Lipika Goyal, MD

Assistant Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Harvard Medical School
Attending Physician
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Faculty
R. Kate Kelley, MD

Associate Professor
Division of Hematology and Oncology
University of California, San Francisco
San Francisco, California

Faculty
Amit Singal, MD

Chief of Hepatology
Medical Director
, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

Goal Statement
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate current and emerging therapies into the treatment of patients with HCC and BTC.

Target Audience
This educational program is intended for medical oncologists, hepatologists, radiation oncologists, surgical oncologists, and other healthcare providers who treat patients with HCC and BTC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate clinical data on the use of immune checkpoint inhibitor–based treatment approaches for patients with early or intermediate-stage HCC
  • Plan optimal, individualized therapy approaches using immune checkpoint inhibitor–based regimens for patients with advanced or metastatic HCC, as clinically appropriate
  • Identify patients with biliary tract cancers most likely to benefit from immune checkpoint inhibitor–based combination therapy based on tumor characteristics, previous treatment, and patient characteristics and preferences
  • Develop strategies to identify and mitigate unique adverse events associated with immune checkpoint inhibitor therapy in patients with HCC or BTC

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.